Hormonal treatment remains a main stay of systemic therapy for prostate cancer despite recent developments in chemotherapy and intensive research with targeted drugs and immunotherapy. Its efficacy in palliative management of advanced disease has prompted its use as an adjunct to local treatments in earlier disease stages, but results of trials in some settings remain inconclusive.
Leave a Reply